key: cord-0929547-6jmofuyl
authors: Youngster, Michal; Avraham, Sarit; Yaakov, Odelia; Landau Rabbi, Moran; Gat, Itai; Yerushalmi, Gil; Sverdlove, Rachael; Baum, Micha; Maman, Ettie; Hourvitz, Ariel; Kedem, Alon
title: IVF under COVID-19: treatment outcomes of fresh ART cycles
date: 2022-02-25
journal: Hum Reprod
DOI: 10.1093/humrep/deac043
sha: 16a31c885963e0fe5f83f65f2ee6aa87368d426d
doc_id: 929547
cord_uid: 6jmofuyl

STUDY QUESTION: Does prior SARS-CoV-2 infection in women undergoing fertility treatments affect the outcomes of fresh ART cycles? SUMMARY ANSWER: SARS-CoV-2 infection does not affect fresh ART treatment outcomes, except for a possible long term negative effect on oocyte yield (>180 days post infection). WHAT IS KNOWN ALREADY: A single previous study suggested no evidence that a history of asymptomatic or mild SARS-CoV-2 infection in females caused impairment of fresh ART treatment outcomes. STUDY DESIGN, SIZE, DURATION: Retrospective cohort study, including all SARS-CoV-2 infected women who underwent fresh ART cycles within a year from infection (the first cycle post infection), between October 2020 and June 2021, matched to non-diagnosed controls. PARTICIPANTS/MATERIALS, SETTING, METHODS: Patients from two large IVF units in Israel who were infected with SARS-CoV-2 and later underwent fresh ART cycles were matched by age to non-diagnosed, non-vaccinated controls. Demographics, cycle characteristics and cycle outcomes, including oocyte yield, maturation rate, fertilization rate, number of frozen embryos per cycle, and clinical pregnancy rates, were compared between groups. MAIN RESULTS AND THE ROLE OF CHANCE: One hundred and twenty-one infected patients and 121 controls who underwent fresh ART cycles were included. Oocyte yield (12.50 versus 11.29; p = 0.169) and mature oocyte rate (78% versus 82%; p = 0.144) in all fresh cycles were similar between groups, as were fertilization rates, number of frozen embryos per cycle and clinical pregnancy rates (43% versus 40%; p = 0.737) in fresh cycles with an embryo transfer. In a logistic regression model, SARS-CoV-2 infection more than 180 days prior to retrieval had a negative effect on oocyte yield (p = 0.018, Slope=-4.08, 95% CI -7.41 – -0.75), although the sample size was small. LIMITATIONS, REASONS FOR CAUTION: A retrospective study with data that was not uniformly generated under a study protocol, no antibody testing for the control group. WIDER IMPLICATIONS OF THE FINDINGS: The study findings suggest that SARS-CoV-2 infection does not affect treatment outcomes, including oocyte yield, fertilization and maturation rate, number of good quality embryos, and clinical pregnancy rates, in fresh ART cycles, except for a possible long term negative effect on oocyte yield when retrieval occurs > 180 days post SARS-CoV-2 infection. Further studies are warranted to support these findings. STUDY FUNDING/COMPETING INTEREST(S): None. TRIAL REGISTRATION NUMBER: 0010-21-HMC, 0094-21-ASF

Abstract generated under a study protocol, no antibody testing for the control group. 48

Corona Virus disease 19 (COVID-19) is caused by severe acute respiratory 72 syndrome coronavirus-2 (SARS-CoV-2). SARS-CoV-2 enters target host cells via the cellular 73 receptor angiotensin-converting enzyme 2 (ACE2) and the cellular transmembrane protease 74 serine-2 (TMPRSS2) (Lukassen et al., 2020) . In theory, organs with a high expression of 75 

One hundred and twenty-one women in the study group and 121 women in the 148 control group were included (Table I) Table SI) . (Table II) . In a sub analysis of 164 the linear regression model according to time from SARS-CoV-2 infection (Table II) , while 165 age remained a significant factor, the COVID status was not significant in the first two 166 groups (≤90 day, 90-180 days). In the small subgroup (29 patients) with a past infection > 167 180 days, a negative effect on oocyte yield was observed (p=0.018, slope=-4.08, 95% CI - 

Ninety-one of 121 women in the COVID group and 94 of 121 women in the control group 172 underwent embryo transfer and were included in the pregnancy rate analysis (Table III) . Of 173 the 57 patients who did not undergo embryo transfer and were excluded from this analysis 174 the majority were treated for fertility preservation (medical or social), underwent genetic 175 testing, or had a hyper-response preventing embryo transfer. Only one patient from each 176 group, both with an infertility diagnosis of premature ovarian insufficiency, did not undergo 177 embryo transfer, without a pre-planned indication. 178

Demographic characteristics were similar in both groups (Supplementary Table SII) . 179

Partners' COVID status significantly differed between groups with higher rates of recovered 180 and vaccinated partners in the COVID group (p<0.001). Cycle characteristics were similar 181 between groups except for the fertilization method, with a higher intra-cytoplasmic sperm 182 performed showing no effect of past SARS-CoV-2 infection on pregnancy rates (p=0.889). 197

Patient age and endometrial thickness were the only significant variables. The same model 198 was applied for patients having an embryo transfer within 90 days of SARS-CoV-2 infection, 199

with patient age being the only significant variable (Table IV) Further analysis of women infected more than 180 days prior to treatment was 240 performed to assess for long-term effects as a result of possible damage to the primordial 241 follicles or during the initial recruitment process. In this subgroup of patients, lower oocyte 242 yields were observed, while all other parameters were unaffected. It should be noted 243 however that the sample size was small, thus cautious interpretation of the results is 244

In univariate analyses of cycles with embryo transfer, a significant difference was 246 observed in the fertilization method. ICSI was more commonly used in the COVID group 247

whereas IVF was more commonly used in the control group, despite the fact that there was 248 no difference in infertility causes. This may possibly be explained by the lab evaluation of 249 partner sperm prior to fertilization. Partners' COVID status was, as expected, more likely to 250

show past infection in the COVID group. Prior studies have reported a decrease in sperm 251 parameters, potentially explaining the higher ICSI rates in the COVID group. However, 252 fertilization method was not found to be significantly associated with the pregnancy rate in 253 the multivariate regression model. 254

The strength of our study is our relatively large sample of women that tested positive 255 for SARS-CoV-2, allowing us to evaluate different stages of the IVF procedure, including 256 oocyte development, maturation and embryo implantation, at different time points after the 257 acute infection. The main limitation of the study is its retrospective nature, with the inherent 258 biases of collecting data that was not uniformly generated under a study protocol. Another 259 caveat is the lack of sperm analyses, which, especially given the possible effect of SARS-260

CoV-2 infection on sperm parameters and significant difference in rates of recovered 261 partners between groups, may explain the significant difference in the fertilization method 262 utilized. Even so, fertilization rates and embryo grade were similar between groups. Another 263 limitation is the fact that women in the control group were chosen based on medical history 264 and did not undergo antibody testing. 265

In conclusion, recent past SARS-CoV-2 infection, less than 180 days prior to IVF 266 treatment, did not affect oocyte yield, fertilization, maturation and clinical pregnancy rates in 267 fresh IVF cycles. A possible long-term effect (>180 days) compromising oocyte yield was 268 observed. Further studies are warranted in order to support these findings with special 269 attention to the long-term effects. 

The physiology of folliculogenesis: The role of novel growth 309 factors

Semen impairment and occurrence of SARS-CoV-2 virus in 312 semen after recovery from COVID-19

Dynamics of follicular growth in the human: a model from preliminary results

Absence of SARS-CoV-2 in semen of a COVID-19 patient cohort

CoV-2 infection risk assessment in the endometrium: viral infection-related gene 321 expression across the menstrual cycle

Comparison Between Two Assays for Measuring Seminal Oxidative Stress and their 324

Relationship with Sperm DNA Fragmentation and Semen Parameters

COVID-19/ACE2 on the female reproductive system. Mol Hum Reprod

Clinical Characteristics and Results of Semen Tests 333

Among Men With Coronavirus Disease

Potential 336 risks of SARS-CoV-2 infection on reproductive health

The role of oxidative stress in influenza virus 339 infection. Microbes Infect

SARS -CoV-2 receptor ACE 2 and TMPRSS 2 are primarily 342 expressed in bronchial transient secretory cells

Suspension of fertility treatment during the 345

COVID-19 pandemic: views, emotional reactions and psychological distress among 346 women undergoing fertility treatment

Oxidative stress and alterations in DNA 349 methylation: two sides of the same coin in reproduction

Angiotensin-352 (1-7), its receptor Mas, and the angiotensin-converting enzyme type 2 are expressed in 353 the human ovary

Lombardy County (Italy) during the peak COVID-19 pandemic